Jordan, K., & Müller-Tidow, C. (2018). Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?: A systematic review and meta-analysis. Supportive care in cancer, 26(1), . https://doi.org/10.1007/s00520-017-3857-7
Chicago-Zitierstil (17. Ausg.)Jordan, Karin, und Carsten Müller-Tidow. "Is the Addition of a Neurokinin-1 Receptor Antagonist Beneficial in Moderately Emetogenic Chemotherapy?: A Systematic Review and Meta-analysis." Supportive Care in Cancer 26, no. 1 (2018). https://doi.org/10.1007/s00520-017-3857-7.
MLA-Zitierstil (9. Ausg.)Jordan, Karin, und Carsten Müller-Tidow. "Is the Addition of a Neurokinin-1 Receptor Antagonist Beneficial in Moderately Emetogenic Chemotherapy?: A Systematic Review and Meta-analysis." Supportive Care in Cancer, vol. 26, no. 1, 2018, https://doi.org/10.1007/s00520-017-3857-7.